21:57 , Jul 10, 2018 |  BC Extra  |  Company News

Management tracks: G1, Collegium, Nimbus

Cancer company G1 Therapeutics Inc. (NASDAQ:GTHX) hired John Demaree as chief commercial officer and Stillman Hanson as general counsel. Demaree was VP of oncology marketing at Astellas Pharma Inc. (Tokyo:4503). Hanson was associate general counsel...
04:56 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Syntimmune reports Phase Ia data for autoimmune disease candidate

Syntimmune Inc. (Waltham, Mass.) reported data from a Phase Ia trial in 31 healthy volunteers showing that single ascending doses of IgG-mediated autoimmune disease candidate IV SYNT001 were well tolerated with no serious adverse events...
23:54 , Jan 4, 2018 |  BC Extra  |  Company News

Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
19:10 , Jul 6, 2017 |  BioCentury  |  Finance

Planting seeds

With a $1.5 billion open-ended fund, Apple Tree Partners is plowing large sums into a handful of translational start-ups with the goal of eventually having at least one portfolio company grow into a commercial-stage large...
20:30 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Autoimmune play Syntimmune raises $50M

On June 21, autoimmune disease company Syntimmune Inc. (New York, N.Y.) raised $50 million a series B round led by existing investor Apple Tree Partners with a $48 million investment. Existing investors Partners Innovation Fund,...
17:47 , Jun 21, 2017 |  BC Extra  |  Financial News

Autoimmune play Syntimmune raises $50M

Autoimmune disease company Syntimmune Inc. (New York, N.Y.) raised $50 million in a series B round. Existing investor Apple Tree Partners invested $48 million to lead the round. Also participating were existing investors Partners Innovation...
19:06 , Jan 6, 2017 |  BioCentury  |  Emerging Company Profile

Gobbling globulins

Syntimmune Inc. is targeting a receptor that mediates the life span and activity of immunoglobulin G to control autoimmune disease more precisely and potentially more safely than broadly acting agents. The company aims to differentiate...
18:22 , Nov 18, 2016 |  BC Week In Review  |  Financial News

Syntimmune completes venture financing

Syntimmune raised $8 million in the final tranche of a series A round, bringing the total raised to $28 million. Syntimmune Inc., New York, N.Y.  ...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Financial News

Syntimmune financial update

Syntimmune Inc., New York, N.Y.   Business: Autoimmune   Date announced: 2016-03-22   Note: Syntimmune raised $10 million in a second tranche of a planned $26 million series A financing, bringing the total raised to $18 million. The...